Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1107 of 6351
-
New drug combo aims to stall lymphoma without chemo
Disease control CompletedThe purpose of this study was to evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in prolonging progression free survival (PFS) in patients with relapsed iNHL who have received one or more lines of treatment, including…
Phase 3 • Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Small cash rewards may keep HIV-positive mothers in treatment — a trial puts the idea to the test
Disease control CompletedA randomized controlled trial will be conducted to assess the effectiveness of conditional cash transfers (CCTs) at increasing retention in prevention of mother-to-child transmission (PMTCT) services specifically, in relation to pickup of ARV drugs for infected mothers, delivery …
Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Could adding palbociclib to hormone therapy prevent breast cancer return?
Disease control OngoingThis is a prospective, two arm, international, multicenter, randomized, open-label Phase III study evaluating the addition of 2 years of palbociclib to standard adjuvant endocrine therapy for patients with HR+ / HER2- early breast cancer (EBC). The purpose of the PALLAS study is…
Phase 3 • Sponsor: Alliance Foundation Trials, LLC. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy shows promise for aggressive leukemia
Disease control CompletedIn this single-center, open-label, no control,prospective clinical trial, a total of 30 Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) patients will be enrolled. Dasatinib 100 mg per day will be given orally along with combination chemotherapy starting day…
Phase 2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New combo therapy aims to tackle returning lymphoma
Disease control OngoingThis phase II trial studies how well rituximab and pembrolizumab with or without lenalidomide works in treating patients with follicular lymphoma and diffuse large B-cell lymphoma that has returned after a period of improvement. Immunotherapy with monoclonal antibodies, such as r…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New malaria vaccine for pregnant women shows promise in lab tests
Vaccine Recruiting nowBackground: \- Malaria is a disease that affects many people in African countries. It is caused by germs that are spread by mosquito bites. It can be fatal if not diagnosed and treated right away. Children younger than 5 and pregnant women are most at risk to get malaria. Resear…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Vaccine
Last updated Aug 12, 2026 00:00 UTC
-
Lab-Grown immune cells take on dangerous viruses in vulnerable patients
Disease control Recruiting nowThis phase II trial studies how well donor cytotoxic T lymphocytes work in treating patients with malignancies with BK and/or JC virus. Cytotoxic T lymphocytes are made from donated blood cells that are grown in the laboratory and are designed to kill viruses that can cause infec…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Immunotherapy-Radiation combo shows promise in tough lung cancer
Disease control CompletedThis phase I trial studies the side effects and best dose of pembrolizumab when given together with chemoradiotherapy or radiation therapy in treating patients with small cell lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug combo shows promise in lung cancer fight
Disease control OngoingThis is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growt…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New dosing study aims to tame Drug-Resistant leukemia
Disease control CompletedThe purpose of this study is to characterize the efficacy of ponatinib administered in 3 starting doses (45 mg, 30 mg, and 15 mg daily) in participants with CP-CML who are resistant to prior tyrosine-kinase inhibitor (TKI) therapy or have T315I mutation, as measured by \<=1 % Bre…
Phase 2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Can a cancer drug stop AML from coming back?
Disease control OngoingThis phase II trial studies how well nivolumab works in eliminating any remaining cancer cells and preventing cancer from returning in patients with acute myeloid leukemia that had a decrease in or disappearance of signs and symptoms of cancer after receiving chemotherapy. Immuno…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Lung cancer showdown: surgery or radiation – which saves more lives?
Disease control Recruiting nowTo Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC
Phase 3 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New drug combo shows promise for rare bone marrow failure
Disease control CompletedThe null hypothesis of no difference in CR% at 3 months between the arms will be tested against the alternative of a difference in CR% at an alpha level of .05 by assessing the odds ratio for arm yielded by this model.
Phase 3 • Sponsor: European Society for Blood and Marrow Transplantation • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
MRI scans could help decide who needs a heart defibrillator
Disease control CompletedContemporary heart failure (HF) guidelines recommend insertion of a primary prevention implantable defibrillator (ICD) in patients with left ventricular ejection fraction less than 35% (LVEF \< 35%) on maximally tolerated medical therapy. Nevertheless, there are a substantial num…
Sponsor: Flinders University • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New combo therapy shows promise for older leukemia patients
Disease control OngoingThis phase II trial studies the side effects and how well blinatumomab and combination chemotherapy or dasatinib, prednisone, and blinatumomab work in treating older patients with acute lymphoblastic leukemia. Immunotherapy with monoclonal antibodies, such as blinatumomab, may he…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New drug combo shows promise for kids with rare immune disease
Disease control CompletedThe purpose of this project is to study the number of surviving patients until hematopoietic stem cell transplantation (HSCT) after first line treatment of hemophagocytic lymphohistiocytosis (HLH) by Alemtuzumab
Phase 1/2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New drug cocktail aims to improve remission in older leukemia patients
Disease control OngoingThe purpose of this study is to test the safety of a new combination of three oral drugs in Ph+ ALL. These drugs are dexamethasone, dasatinib, and ruxolitinib. All three drugs have been studied before in humans. This is a phase I study in which ruxolitinib dose will start low fo…
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New drug cocktail shows promise for Tough-to-Treat ovarian cancer
Disease control OngoingBackground: \- Durvalumab is a drug that may help people s immune systems respond to and kill cancer cells. Olaparib is a drug that may inhibit repairing DNA damage of cancer cells. Cediranib is a drug that may stop the blood vessel growth of cancer cells. This study has two com…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Promising new drug shows hope for rare anemia patients
Disease control CompletedStudy AG348-C-003 is a multicenter study designed to evaluate the safety and efficacy of different dose levels of AG-348 (mitapivat) in participants with PK deficiency.
Phase 2 • Sponsor: Agios Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Could a single shot of naloxone after a seizure save lives?
Disease control CompletedSudden unexpected death in epilepsy (SUDEP) primarily affects young adults with drug-resistant epilepsy, with an incidence of about 0.4%/year. The diagnosis of SUDEP requires that anamnestic data and post-mortem examination do not reveal a structural or toxicological cause for de…
Phase 3 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC